Seminars in Oncology Nursing
Volume 23, Issue 1 , Pages 37-45 , February 2007

Targeting Metastatic and Advanced Breast Cancer

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA: Cancer J Clin. 2006;56:106–130
  2. Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In:  Harris J,  Lippman M,  Morrow M,  Osborne C editor. Diseases of the Breast. Ed 3. Philadelphia, PA: Lippincott Williams & Wilkins; 2004;p. 1101–1162
  3. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005;23:5386–5403
  4. Garrett C. Targeted therapy: The fast pace of progress. Cancer Control. 2005;12:71–72
  5. Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control. 2005;12:73–81
  6. Kaklamani V, O’Regan RM. New targeted therapies in breast cancer. Semin Oncol. 2004;31(suppl 4):420–425
  7. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist. 2003;8:335–341
  8. Pegram MD, Pietras R, Bajamonde A, et al. Targeted therapy: wave of the future. J Clin Oncol. 2005;23:1776–1781
  9. Jensen E, DeSombre E, Jungblut P. Estrogen Receptors in Hormone Responsive Tissues and Tumors. Chicago, IL: University of Chicago Press; 1969;
  10. Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(suppl 4):S3–S8
  11. Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 1997;15:1–8
  12. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;28:2639–2648
  13. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726
  14. Bloom K, De La Torre-Bueno J, Press M, et al. Comparison of HER-2/neu analysis using FISH and IHC when HercepTest is scored using conventional microscopy and image analysis [abstract 416]. Breast Cancer Res Treat. 2000;64:99
  15. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use?. J Pathol. 2003;199:411–417
  16. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095–3105
  17. Tawfik OW, Kimler BF, Davis M, et al. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology. 2006;48:258–267
  18. Genentech Inc. Herceptin prescribing information. Available at: http://www.gene.com/gene/products/information/oncology/herceptin/insert.jsp. (accessed February 4, 2006).
  19. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics. 2004;3:379–398
  20. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  21. Pegram MD, Konecny GE, O’Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96:739–749
  22. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004;22:322–329
  23. Crone SAZ, Zhao YY, Fan L, Gu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med. 2002;8:459–465
  24. Hudis C, Seidman A, Paton V, et al. Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials [abstract 24]. Breast Cancer Res Treat. 1998;50:232
  25. Vogel CL, Franco SX. Clinical experience with trastuzumab (Herceptin). Breast J. 2003;9:452–462
  26. Leyland-Jones B, Gelmon K, Ayoub J-P, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 2003;21:3965–3971
  27. Tripathy D. Targeted therapies in breast cancer. Breast J. 2005;11(suppl 1):S30–S35
  28. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22:1063–1070
  29. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91:639–643
  30. Loebbecke M, Fuchs I, Evers K. Efficacy of Herceptin treatment on brain metastasis in women with HER2 overexpressing breast cancer [abstract 521]. Breast Cancer Res Treat. 2001;69:302;Proceedings of the 24th Annual San Antonio Breast Cancer Symposium
  31. Lower EE, Blau R, Bismayer J. Increased brain metastasis detected in metastatic breast cancer patients receiving Herceptin [abstract 357]. Br Cancer Res Treat. 2001;69:271
  32. Miller KD, Weathers T, Haney LG. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival [abstract 214]. Br Cancer Res Treat. 2001;69:240
  33. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592–1600
  34. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221
  35. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990;82:4–6
  36. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185–188
  37. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst. 1992;84:1875–1887
  38. Muehlbauer PM. Anti-angiogenesis in cancer therapy. Semin Oncol Nurs. 2003;19:180–192
  39. Sledge GW, Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer. 2003;39:1668–1675
  40. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257
  41. Gasparini G, Longo R, Torino G, et al. Therapy of breast cancer with molecular targeting agents. Ann Oncol. 2005;16(Suppl 4):iv28–iv36
  42. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–1026
  43. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol. 2005;23:1782–1789
  44. Hoff PM. Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Semin Oncol. 2004;31(Suppl 17):17–21
  45. Viele CS. Keys to unlock cancer: targeted therapy. Oncol Nurs Forum. 2005;32:935–940
  46. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30:117–124
  47. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–799
  48. Miller K, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100) [abstract 3]. Br Cancer Res Treat. 2006;94:S6
  49. Genentech Inc. Avastin prescribing information. Available at: http://www.gene.com/gene/products/information/oncology/avastin/insert.jsp. (accessed 12/20/06).
  50. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  51. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  52. Martel CL, Presant CA, Ebrahimi BU, et al. Bevacizumab-related toxicities: association of hypertension and proteinuria. Comm Oncol. 2006;3:90–93
  53. Franson PJ, Lapka DV. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer. Clin J Oncol Nurs. 2005;9:55–60
  54. Novotny WF, Holmgren E, Griffing S, et al. Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage (PH) in patients with advanced NSCLC receiving bevacizumab (BV) [abstract]. J Clin Oncol. 2001;20:1318
  55. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–410
  56. Middleton G, Lapka DV. Bevacizumab (Avastin). Clin J Oncol Nurs. 2004;8:666–669
  57. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94:1593–1611
  58. Burris HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9(suppl 3):10–15
  59. Geyer CE, Forster J, Lundquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743
  60. Blackwell K, Kaplan EH, Franco S, et al. A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing regimens. Ann Oncol. 2004;15(suppl 3):iii27;Paper presented at the 29th European Society for Medical Oncology (ESMO) Congress, Oct 29-Nov 3, 2004, Vienna, Austria. [abstr 103]
  61. Burstein H, Storniolo AM, Franco S, et al. A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens [abstract 1040]. Ann Oncol. 2004;15(suppl 3):iii27–iii28
  62. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against Her-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66:1630–1639
  63. Spector NL, Blackwell K, Hurley J, et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response [abstract]. Proc Am Soc Clin Oncol. 2006;24:502
  64. Gomez HL, Chavez MA, Doval DC, et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. J Clin Oncol. 2005;23(suppl 16):3046
  65. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer [abstract]. Proc Am Soc Clin Oncol. 2006;24:503
  66. Miller KD, Burstein HJ, Elias AD, et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients with previously treated metastatic breast cancer (MBC). J Clin Oncol. 2005;23:563
  67. Kim C, Bryant J, Horne A, et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggest pro-apoptotic function of dysregulated cMYC in vivo [abstract 46]. Br Cancer Res Treat. 2006;94:S6
  68. Tripathy D. Update on targeted therapy for breast cancer. 2005;Proceedings of the Annual Symposium of the American Society of Breast Disease; April 14-16, 2005, Las Vegas, NV

PII: S0749-2081(06)00160-4

doi: 10.1016/j.soncn.2006.11.007

Seminars in Oncology Nursing
Volume 23, Issue 1 , Pages 37-45 , February 2007

Article Tools

* Image Usage & Resolution